论文部分内容阅读
辅助性化学－免疫治疗应用于Ⅱ期、ⅢＡ期原发性肺癌切除术后患者过去的十年中，肺癌患者的预后有了一定改善，但进展期肺癌病例的结局仍令人担忧，ⅢＡ期根治术（或全切术）后５年生存率约２０～３０％。为了改善进展期肺癌患者的预后，人们做了很多尝试。有人应用术后化...
The use of adjuvant chemo-immunotherapy in patients with stage II and IIIA primary resection of lung cancer has improved the prognosis of patients with lung cancer in the past decade, but the outcome of advanced lung cancer remains worrying. Stage IIIA The 5-year survival rate after radical resection (or total resection) is approximately 20-30%. In order to improve the prognosis of patients with advanced lung cancer, many attempts have been made. Some people apply postoperative...